QUOTE AND NEWS
Forbes  Jun 21  Comment 
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on June 14, Bruker Corp's CEO, Frank H. Laukien, invested $99,958.53 into 4,174 shares of BRKR, for a cost...
Reuters  Jun 20  Comment 
* Financial details of asset purchase agreement were not disclosed
SeekingAlpha  May 17  Comment 
Benzinga  May 5  Comment 
BTIG has downgraded Bruker Corporation (NASDAQ: BRKR) to Neutral from Outperform, saying the "margin story continues to play out but [we] are hesitant to expect upside to its current organic growth forecasts this early in 2016." The scientific...
Benzinga  Mar 4  Comment 
J C Penney Company Inc (NYSE: JCP) shares gained 2.31 percent to reach a new 52-week high of $11.09. Evercore ISI upgraded the rating for J C Penney from Hold to Buy, while raising the price target from $8 to $15. Philip Morris International...
Benzinga  Mar 1  Comment 
Barclays initiated coverage on Bruker Corporation (NASDAQ: BRKR) with a Overweight rating. The target price for Bruker is set to $30. Bruker shares closed at $25.98 on Monday. Analysts at BTIG Research initiated coverage on bluebird bio Inc ...
SeekingAlpha  Feb 22  Comment 
SeekingAlpha  Feb 22  Comment 




 
TOP CONTRIBUTORS

Bruker Bioscience manufactures scientific instruments for companies in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis. It develops products that utilize magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology and infrared and Raman molecular spectroscopy technologies. They also manufacture superconducting materials and devices. Bruker Bioscience is a global company, but primarily sells it products in the Americas, Europe, and Asia. Due to the capital intense nature of its products customers may defer spending in tough economic years or to the last part of the year, leading to seasonality and unpredictable revenues.[1]

Business Growth

For 2010 the company reported revenue of $1,304.9 million, up 17.1% as compared to 2009. This increase was due to revenues attributable to recent acquisitions, increases in sales of its core technologies, particularly in magnetic resonance, X-ray and mass spectrometry, and an increase in demand for its low temperature superconducting wire.[1]

Trends and Forces

Bruker's revenues can fluctuate according to capital spending patterns of customers

Bruker's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (for example, NIH funding is distributed to labs towards the end of the calendar year). They may also defer the purchase of capital intensive equipment in slow years such as the 2008 financial crisis. Bruker's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years, but is not expected to increase in the near future. Bruker's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects Bruker's sales revenues.[1]

Competition

Bruker competes with many companies that have signifcantly more financial, technical, and marketing capabilities. To be successful it must create products that can compete based on technolgy, speed to market, and cost. Some of its toughest competitors include[1]:



References

  1. 1.0 1.1 1.2 1.3 Bruker BioSciences 2011 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki